Global Finance News
02 Oct 2026, 18:30
Johnson & Johnson Reports Two-Year ICOTYDE Data Showing Durable Skin Clearance in Plaque Psoriasis
Johnson & Johnson reported new two-year Phase 3 data for ICOTYDE, or icotrokinra, showing sustained skin clearance in patients with plaque psoriasis affecting difficult-to-treat areas including the scalp, genitals, hands and feet.
In the ICONIC-TOTAL study, 70% of ICOTYDE-treated patients achieved clear or almost clear skin at Week 112, up from 57% at Week 16. Complete clearance rates at Week 112 reached 60% for scalp psoriasis, 89% for genital psoriasis and 63% for psoriasis affecting the hands or feet.
Nail psoriasis also continued to improve over time, with the average improvement in the modified Nail Psoriasis Severity Index reaching 71% at Week 112.
Safety findings through two years remained consistent with ICOTYDE’s established safety profile, with no new safety signals identified.
ICOTYDE is a once-daily oral peptide designed to block the IL-23 receptor. It is approved in the U.S. for moderate-to-severe plaque psoriasis in adults and patients aged 12 and older who meet treatment criteria, and is also approved in Europe, Japan and China.
The long-term results strengthen Johnson & Johnson’s case for ICOTYDE as an oral systemic treatment option, particularly for patients with psoriasis affecting sensitive or highly visible areas where treatment can be especially challenging.
Johnson & Johnson reported new two-year Phase 3 data for ICOTYDE, or icotrokinra, showing sustained skin clearance in patients with plaque psoriasis affecting difficult-to-treat areas including the scalp, genitals, hands and feet.
In the ICONIC-TOTAL study, 70% of ICOTYDE-treated patients achieved clear or almost clear skin at Week 112, up from 57% at Week 16. Complete clearance rates at Week 112 reached 60% for scalp psoriasis, 89% for genital psoriasis and 63% for psoriasis affecting the hands or feet.
Nail psoriasis also continued to improve over time, with the average improvement in the modified Nail Psoriasis Severity Index reaching 71% at Week 112.
Safety findings through two years remained consistent with ICOTYDE’s established safety profile, with no new safety signals identified.
ICOTYDE is a once-daily oral peptide designed to block the IL-23 receptor. It is approved in the U.S. for moderate-to-severe plaque psoriasis in adults and patients aged 12 and older who meet treatment criteria, and is also approved in Europe, Japan and China.
The long-term results strengthen Johnson & Johnson’s case for ICOTYDE as an oral systemic treatment option, particularly for patients with psoriasis affecting sensitive or highly visible areas where treatment can be especially challenging.
